Login to Your Account

Financings Roundup

Monday, September 24, 2012
• Actinium Pharmaceuticals Inc., of New York, said it intends to raise up to $20 million in new funds to be used for further clinical development of immunotherapeutic candidates Actimab-A and lomab-B in hematologic malignancies and for continued preclinical development of additional drug candidates in solid cancer indications, as well as for general corporate purposes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription